Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSABP B-47 / ICORG 11-24 trastuzumab adjuvant trial in HER2-low breast cancer
2011-004943-32Phase 3Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Invasive disease-free survival. Started Oct 2011; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-004943-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004943-32.